COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

AMG 386 Drug-Drug Interaction Study With Paclitaxel

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01992341
Recruitment Status : Completed
First Posted : November 25, 2013
Last Update Posted : September 23, 2014
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to evaluate the pharmacokinetics of paclitaxel when given alone and in combination with AMG 386 to determine whether AMG 386 alters the pharmacokinetics of paclitaxel

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Drug: AMG 386 Drug: Paclitaxel Phase 1

Detailed Description:
Eligible subjects enrolled in the study will begin receiving paclitaxel on a three weeks on / one week off schedule at study day 1 and weekly AMG 386 beginning at study day 8. The pharmacokinetic portion of the study occurs during the first two study cycles with intensive PK collections on study weeks 1, 6 and 8. Once the pharmacokinetic assessment period is completed, continued combination therapy with AMG 386 and paclitaxel or single-agent AMG 386 will be administered at the investigator's discretion until progression, unacceptable toxicity develops, or study withdrawal.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 35 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Pharmacokinetic Drug-Drug Interaction (DDI) Study of AMG 386 in Combination With Paclitaxel in Adult Subjects With Advanced Solid Tumors
Study Start Date : July 2012
Actual Primary Completion Date : August 2013
Actual Study Completion Date : September 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Drug Reactions
Drug Information available for: Paclitaxel

Arm Intervention/treatment
Experimental: AMG 386 15mg/kg and paclitaxel 80mg/m2 Drug: AMG 386
Weekly 15 mg/kg of AMG 386 in combination with three weeks on/ one week off 80mg/m2 of paclitaxel. Continued therapy with AMG 386 with or without paclitaxel until progression, unacceptable toxicity develops, or study withdrawal.
Other Name: Taxol

Drug: Paclitaxel
Three weeks on/ one week off 80mg/m2 of paclitaxel in combination with weekly 15 mg/kg of AMG 386 . Continued therapy with AMG 386 until progression, unacceptable toxicity develops, or study withdrawal. A cycle consists of 3 weeks on / 1 week off of paclitaxel.

Primary Outcome Measures :
  1. Paclitaxel PK parameters [ Time Frame: 9 weeks ]
    Paclitaxel PK parameters with and without the co-administration of AMG 386.

Secondary Outcome Measures :
  1. AMG 386 PK parameters [ Time Frame: 9 weeks ]
    AMG 386 PK steady state PK parameters with and without paclitaxel co-administration

  2. Safety [ Time Frame: Average of 6 months ]
    Subject incidence of treatment-emergent adverse events: Assessments include physical examinations, vitals, clinical laboratories, and electrocardiograms (ECG) • Results of safety laboratory tests, vital sign measurements, and ECG measurments

  3. Safety [ Time Frame: Average of 6 months ]
    Incidence of anti-AMG 386 antibody formation

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men or women ≥ 18 years of age
  • Have a pathologically documented, and definitely diagnosed, advanced solid tumor that is refractory to standard treatment, or for which no curative therapy is available
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • Normal or clinically acceptable ECG (12 lead reporting PR, QRS, QTc)

Exclusion Criteria:

  • Subjects with gastric cancer or any malignancy with purely squamous cell histology
  • Known history of primary central nervous system (CNS) tumors or CNS metastases
  • Myocardial infarction within 1 year before study day 1, unstable or uncontrolled disease/condition related to or affecting cardiac function
  • History of stroke, arterial or venous thrombosis, or pulmonary embolism within 1 year before study day 1
  • A baseline ECG QTc interval > 450 msec
  • Active grade 2 or greater peripheral vascular disease
  • History of pulmonary hemorrhage or gross hemoptysis within 6 months before study day 1
  • Non-healing wound, ulcer (including gastrointestinal) or fracture
  • Known positive test for human immunodeficiency virus infection, or active hepatitis B or hepatitis C infection
  • Major surgery within 1 month before study day 1
  • Concurrent antitumor treatment within 4 weeks (6 weeks for nitrosoureas or mitomycin) before study day 1
  • Unable to tolerate IV administration or repeated blood withdrawal
  • Hypersensitivity to paclitaxel or drugs using the vehicle cremophor
  • Known sensitivity to mammalian-derived products, bacterially-produced proteins, or any of the products to be administered during dosing
  • Chronic neuropathy grade ≥ 1
  • Concurrent or prior treatment with 2C8 and 3A4 substrates
  • Enrolled in or has not yet completed at least 30 days (prior to study day 1) since ending other investigational device or drug, or currently receiving other investigational treatment.
  • Men and woman of reproductive potential, unwilling to practice a highly effective method of birth control for the duration of the study and an additional 6 months after the last dose of AMG 386
  • Women who are lactating/breastfeeding
  • Women with a positive pregnancy test
  • Women planning to become pregnant during the duration of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01992341

Layout table for location information
United States, Colorado
University of Colorado Cancer Center
Aurora, Colorado, United States, 80045
United States, Utah
University of Utah Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112
Sponsors and Collaborators
Layout table for investigator information
Study Director: MD Amgen
Additional Information:
Layout table for additonal information
Responsible Party: Amgen Identifier: NCT01992341    
Other Study ID Numbers: 20101151
First Posted: November 25, 2013    Key Record Dates
Last Update Posted: September 23, 2014
Last Verified: September 2014
Keywords provided by Amgen:
Additional relevant MeSH terms:
Layout table for MeSH terms
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors